title: Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications.
abstract: OBJECTIVE
  To evaluate and compare the recurrence rates and complications between 2 therapeutic methods for primary pterygium: subconjunctival injection of mitomycin C (MMC) 1 month before bare scleral excision and conjunctival rotational flap with intraoperative MMC use.
  
  
  METHODS
  Prospective, interventional, randomized clinical trial.
  
  
  METHODS
  setting: Institutional clinical trial in a tertiary, specialty eye hospital. study population and intervention: We included 82 eyes diagnosed with primary pterygium and randomly allocated them into 2 groups. Group A consisted of 36 eyes treated with subconjunctival injection of 0.02% MMC 1 month before bare scleral excision, and group B comprised 46 eyes that underwent conjunctival rotational flap with intraoperative 0.02% MMC for 2 minutes. Follow-up periods were at least 12 months (range, 12 to 18 months). main outcome measure: Recurrence and complication rate in each arm of study.
  
  
  RESULTS
  During the 1-year follow-up, 2 cases of clinical recurrence in third and sixth month of follow-up occurred in group B (recurrence rate, 4.3%). In group A, there was no clinically significant recurrence, but 2 cases of hypovascularity and whitening of sclera at the site of pterygium excision was observed. There was no other serious complication. There was no statistically significant difference between groups for recurrence rate, mean age, sex, or pterygium area.
  
  
  CONCLUSIONS
  Subconjunctival injection of MMC 0.02% (0.1 ml of 0.02% solution) 1 month before bare scleral excision is a quick, easy, and safe surgical procedure and is at least as effective as conjunctival rotational flap with intraoperative MMC for 2 minutes.
authors.affiliation: Khatam Anbia Eye Hospital, Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Khakshoor
authors.forename: Mohammad Etezad
authors.initials: ME
authors.lastname: Razavi
authors.forename: Ramin
authors.initials: R
authors.lastname: Daneshvar
authors.forename: Mohammad Taghi
authors.initials: MT
authors.lastname: Shakeri
authors.forename: Majid Farrokh
authors.initials: MF
authors.lastname: Ghate
authors.forename: Haleh
authors.initials: H
authors.lastname: Ghooshkhanehi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000477:Alkylating Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000187:drug effects / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D007430:Intraoperative Care; D007431:Intraoperative Complications; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D011183:Postoperative Complications; D011300:Preoperative Care; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000601:surgery*; D012008:Recurrence; D012590:Sclera / Q000601:surgery; D013524:Surgical Flaps; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin